Compare Freshworks Inc (FRSH) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Freshworks Inc vs Johnson & Johnson — how do they compare? Freshworks Inc trades at $13.9 (market cap $3.56B), while Johnson & Johnson trades at $261.49 (market cap $618.09B). The key difference: Johnson & Johnson is far larger — about 173.6× Freshworks Inc's market cap, and Johnson & Johnson pays a 2.09% dividend while Freshworks Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Freshworks Inc for 39 Days and Johnson & Johnson for 129 Days on average.
| FRSH | JNJ | |
|---|---|---|
Market Cap | $3.56B | $618.09B |
Volume | 9,066,454 | 6,050,983 |
Sector | Technology | Health |
52-Week High | $13.92 | $278.43 |
52-Week Low | $6.88 | $186.00 |
Typical Hold Time | 39 Days | 129 Days |
Enterprise Value | $2.93B | $646.37B |
Dividend Yield | — | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Freshworks (FRSH) trades at $13.92, up 2.35% today, with strong technical momentum and bullish moving averages. The company achieved its first GAAP profitability in Q2 2026, beating earnings expectations with $0.17 EPS versus $0.13 expected. Revenue growth remains robust at 16% year-over-year, while valuation metrics show a P/E of 21.63 and P/S of 4.28. Recent developments include FedRAMP certification progress and leadership appointments.
The outlook appears positive with analyst consensus at $14.60 price target and 50% buy ratings. Key opportunities include AI monetization and enterprise growth, while risks involve competitive SaaS market pressure and the need to sustain recent profitability gains amid ongoing investments.
Johnson & Johnson (JNJ) trades at $261.44, up 1.16% with a bearish technical signal despite recent earnings beats. The company maintains strong fundamentals with $94.19B revenue, 21.48% net margin, and consistent dividend payments. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with a $286.53 consensus target.
JNJ offers stable growth potential with diversified healthcare operations and robust profitability. Key risks include patent expirations, competitive pressures, and debt levels. Analyst consensus leans bullish with 52.5% buy ratings, though technical indicators suggest near-term caution. The stock presents a balanced opportunity for long-term investors seeking healthcare exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Freshworks Inc
Freshworks Inc provides software as a service platform that enables small and medium-sized businesses to support customers through e-mail, phone, website, and social networks. It offers solutions that serve the needs of users in the CX and ITSM categories, and have also expanded its offering with Sales and Marketing automation products. These product offerings enable organizations to acquire, engage, and better serve their customers and employees.
Read more on FRSH →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
